Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease. Issue 11 (6th July 2021)

• Record Type: Journal Article
• Authors: Kuchay, Mohammad Shafi; Choudhary, Narendra Singh; Gagneja, Sakshi; Mathew, Anu; Bano, Tarannum; Kaur, Parjeet; Bahadur, Bajarang; Singh, Manish Kumar; Gill, Harmandeep Kaur; Wasir, Jasjeet Singh; Sud, Randhir; Mishra, Sunil Kumar
• Is Part Of: Journal of gastroenterology and hepatology. Volume 36:Issue 11(2021)
• Page Start: 3204
• Page End: 3211
• Publication Date: 2021-07-06
• Subjects: duel‐energy X‐ray absorptiometry -- liver fibrosis -- nonalcoholic fatty liver disease -- skeletal muscle mass index -- type 2 diabetes -- transient elastography; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.15595
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Type 2 diabetes (T2D) and low skeletal muscle mass (SMM) are associated with increased risk of nonalcoholic fatty liver disease (NAFLD). However, data regarding the association between low SMM and NAFLD‐related liver fibrosis in individuals with T2D are scarce. Therefore, we aimed to investigate the association between low SMM and liver fibrosis in individuals with T2D and NAFLD. Methods: Controlled attenuation parameter (CAP) of ≥ 248 dB/m was taken as cutoff suggesting NAFLD. Clinically relevant liver fibrosis and advanced liver fibrosis were defined as liver stiffness measurement (LSM) by transient elastography (TE) of ≥ 8.0 and ≥ 9.6 kPa, respectively. SMM was measured using dual energy X‐ray absorptiometry (DEXA). Low SMM was defined as appendicular SMM index of < 7.0 kg/m 2 for men and < 5.4 kg/m 2 for women. Results: Of the 487 consecutive patients with T2D, 366 (75.1%) had NAFLD. Among individuals with NAFLD, 118 (32.2%) and 64 (17.5%) had clinically relevant liver fibrosis and advanced liver fibrosis, respectively. Low SMM was diagnosed in 78 (21.3%) individuals with NAFLD. Patients with low SMM were older (56.1 vs 52.8 years) and had longer duration of diabetes (10.3 vs 8.1 years). Low SMM was an independent risk factor associated with clinically relevant liver fibrosis ( P = 0.002) and advanced liver fibrosis ( P ≤ 0.0001). Associations between low SMM and clinically relevant‐ and advanced liver fibrosis were maintained even after sequential adjustment for confounding variables through the multivariate regression analysis. Conclusions: Low SMM is independently associated with liver fibrosis in individuals with T2D and NAFLD.